{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:27:41Z","timestamp":1791325661135,"version":"4.3.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49860-x","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:58:25Z","timestamp":1782140305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of metformin analogues in targeting signaling molecules of head and neck cancer pathways by computational approaches"],"prefix":"10.1038","volume":"16","author":[{"given":"Payas","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Prasad","family":"Kollur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi M.","family":"Shanthappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawana","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Tenguria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Jagdish","family":"Upadhye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"1","key":"49860_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01297-0","volume":"8","author":"Q Li","year":"2023","unstructured":"Li, Q., Tie, Y., Alu, A., Ma, X. & Shi, H. Targeted therapy for head and neck cancer: Signaling pathways and clinical studies. Signal Transduct. Target. Ther. 8(1), 31. https:\/\/doi.org\/10.1038\/s41392-022-01297-0 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"49860_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1535-6108(04)00090-X","volume":"5","author":"L Mao","year":"2004","unstructured":"Mao, L., Hong, W. K. & Papadimitrakopoulou, V. A. Focus on head and neck cancer. Cancer Cell 5(4), 311\u2013316. https:\/\/doi.org\/10.1016\/S1535-6108(04)00090-X (2004).","journal-title":"Cancer Cell"},{"issue":"10318","key":"49860_CR3","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","volume":"398","author":"MD Mody","year":"2021","unstructured":"Mody, M. D., Rocco, J. W., Yom, S. S., Haddad, R. I. & Saba, N. F. Head and neck cancer. Lancet 398(10318), 2289\u20132299. https:\/\/doi.org\/10.1016\/S0140-6736(21)01550-6 (2021).","journal-title":"Lancet"},{"issue":"1","key":"49860_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89053-6","volume":"15","author":"A Heinolainen","year":"2025","unstructured":"Heinolainen, A., Nguyen, B., Sil\u00e9n, S., Renkonen, R. & Koskinen, M. Survival and data-driven phenotypes in head and neck cancer. Sci. Rep. 15(1), 5985. https:\/\/doi.org\/10.1038\/s41598-025-89053-6 (2025).","journal-title":"Sci. Rep."},{"issue":"3","key":"49860_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74(3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"49860_CR6","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2023.1603","author":"S Bagal","year":"2023","unstructured":"Bagal, S. et al. Head and neck cancer burden in India: An analysis from published data of 37 population-based cancer registries. Ecancermedicalscience https:\/\/doi.org\/10.3332\/ecancer.2023.1603 (2023).","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"49860_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-024-00089-z","volume":"2","author":"CDL Smith","year":"2024","unstructured":"Smith, C. D. L. et al. Head and neck cancer incidence is rising but the sociodemographic profile is unchanging: A population epidemiological study (2001\u20132020). BJC Rep. 2(1), 71. https:\/\/doi.org\/10.1038\/s44276-024-00089-z (2024).","journal-title":"BJC Rep."},{"issue":"7","key":"49860_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071610","volume":"12","author":"Q Jiang","year":"2024","unstructured":"Jiang, Q. et al. The role of the PI3K\/Akt\/mTOR axis in head and neck squamous cell carcinoma. Biomedicines 12(7), 1610. https:\/\/doi.org\/10.3390\/biomedicines12071610 (2024).","journal-title":"Biomedicines"},{"issue":"9","key":"49860_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.702","volume":"5","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Zhang, N., Wen, Y. & Wen, J. Head and neck cancer: Pathogenesis and targeted therapy. MedComm 5(9), e702. https:\/\/doi.org\/10.1002\/mco2.702 (2024).","journal-title":"MedComm"},{"issue":"9625","key":"49860_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","volume":"371","author":"A Argiris","year":"2008","unstructured":"Argiris, A., Karamouzis, M. V., Raben, D. & Ferris, R. L. Head and neck cancer. The Lancet 371(9625), 1695\u20131709. https:\/\/doi.org\/10.1016\/S0140-6736(08)60728-X (2008).","journal-title":"The Lancet"},{"issue":"1","key":"49860_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Primers. 6(1), 92. https:\/\/doi.org\/10.1038\/s41572-020-00224-3 (2020).","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"11","key":"49860_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.56042\/ijbb.v61i11.12051","volume":"61","author":"S Pulakuntla","year":"2024","unstructured":"Pulakuntla, S., Singh, S. A., Kuruvalli, G., Shaik, A. H. & Reddy, V. D. Molecular docking and dynamics analysis to reveal the therapeutic potential of Dostarlimab against novel immune targets in liver cancer. Indian J. Biochem. Biophys. 61(11), 740\u2013755. https:\/\/doi.org\/10.56042\/ijbb.v61i11.12051 (2024).","journal-title":"Indian J. Biochem. Biophys."},{"issue":"33","key":"49860_CR13","doi-asserted-by":"publisher","first-page":"21452","DOI":"10.1039\/D2RA03451D","volume":"12","author":"D Halder","year":"2022","unstructured":"Halder, D., Das, S., R., A. & R. S., J. Molecular docking and dynamics based approach for the identification of kinase inhibitors targeting PI3K\u03b1 against non-small cell lung cancer: A computational study. RSC Adv. 12(33), 21452\u201321467. https:\/\/doi.org\/10.1039\/D2RA03451D (2022).","journal-title":"RSC Adv."},{"issue":"1","key":"49860_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/cbdd.14126","volume":"101","author":"D Stary","year":"2023","unstructured":"Stary, D., Nepovimova, E., Kuca, K. & Bajda, M. Searching for new mTOR kinase inhibitors: Analysis of binding sites and validation of docking protocols. Chem. Biol. Drug Des. 101(1), 103\u2013119. https:\/\/doi.org\/10.1111\/cbdd.14126 (2023).","journal-title":"Chem. Biol. Drug Des."},{"issue":"2","key":"49860_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/jcb.27100","volume":"120","author":"M Rehan","year":"2019","unstructured":"Rehan, M. & Bajouh, O. S. Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer-signaling PI3K\/AKT\/mTOR pathway. J. Cell. Biochem. 120(2), 1328\u20131339. https:\/\/doi.org\/10.1002\/jcb.27100 (2019).","journal-title":"J. Cell. Biochem."},{"issue":"5","key":"49860_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050906","volume":"14","author":"YT-K Nguyen","year":"2022","unstructured":"Nguyen, Y.T.-K. et al. Impairment of glucose metabolism and suppression of stemness in MCF-7\/SC human breast cancer stem cells by Nootkatone. Pharmaceutics 14(5), 906. https:\/\/doi.org\/10.3390\/pharmaceutics14050906 (2022).","journal-title":"Pharmaceutics"},{"issue":"1","key":"49860_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.22159\/ijap.2023v15i1.46570","volume":"15","author":"S Ridwan","year":"2023","unstructured":"Ridwan, S., Erlina, L., Bahtiar, A. & Sukmawati, D. Identification and in silico analysis of inhibitor on the WNT\/\u03b2-catenin signaling pathway as potential drug for colon cancer. Int. J. Appl. Pharm. 15(1), 111\u2013120. https:\/\/doi.org\/10.22159\/ijap.2023v15i1.46570 (2023).","journal-title":"Int. J. Appl. Pharm."},{"issue":"4","key":"49860_CR18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1021\/ci6005036","volume":"47","author":"PK Gadakar","year":"2007","unstructured":"Gadakar, P. K., Phukan, S., Dattatreya, P. & Balaji, V. N. Pose prediction accuracy in docking studies and enrichment of actives in the active site of GSK-3\u03b2. J. Chem. Inf. Model. 47(4), 1446\u20131459. https:\/\/doi.org\/10.1021\/ci6005036 (2007).","journal-title":"J. Chem. Inf. Model."},{"key":"49860_CR19","doi-asserted-by":"publisher","unstructured":"Gill, B. S., Kumar, S. & Navgeet. (2018). Ganoderic acid a targeting \u03b2-catenin in wnt signaling pathway: In silico and in vitro study. Interdiscipl. Sci. Comput. Life Sci. 10(2), 233\u2013243. https:\/\/doi.org\/10.1007\/s12539-016-0182-7","DOI":"10.1007\/s12539-016-0182-7"},{"issue":"17","key":"49860_CR20","doi-asserted-by":"publisher","first-page":"9133","DOI":"10.1080\/07391102.2023.2250465","volume":"42","author":"S Samreen","year":"2024","unstructured":"Samreen, S., Khan, E. & Ahmad, I. Z. Molecular docking and molecular dynamics simulation analysis of bioactive compounds of Cichorium intybus L. seed against hepatocellular carcinoma. J. Biomol. Struct. Dyn. 42(17), 9133\u20139144. https:\/\/doi.org\/10.1080\/07391102.2023.2250465 (2024).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"49860_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1504\/IJMEI.2013.051660","volume":"5","author":"R Subhashini","year":"2013","unstructured":"Subhashini, R. Insilico inhibition of hexokinase-2 to treat cancer cells. Int. J. Med. Eng. Inform. 5(1), 1\u20134. https:\/\/doi.org\/10.1504\/IJMEI.2013.051660 (2013).","journal-title":"Int. J. Med. Eng. Inform."},{"issue":"7","key":"49860_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070810","volume":"15","author":"I Szymczak-Pajor","year":"2022","unstructured":"Szymczak-Pajor, I., Wenclewska, S. & \u015aliwi\u0144ska, A. Metabolic action of metformin. Pharmaceuticals 15(7), 810. https:\/\/doi.org\/10.3390\/ph15070810 (2022).","journal-title":"Pharmaceuticals"},{"issue":"1","key":"49860_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04263-8","volume":"21","author":"Y Hua","year":"2023","unstructured":"Hua, Y. et al. Metformin and cancer hallmarks: Shedding new lights on therapeutic repurposing. J. Transl. Med. 21(1), 403. https:\/\/doi.org\/10.1186\/s12967-023-04263-8 (2023).","journal-title":"J. Transl. Med."},{"key":"49860_CR24","doi-asserted-by":"publisher","unstructured":"Kasznicki, J., Sliwinska, A. & Drzewoski, J. (2014). Metformin in cancer prevention and therapy. In Annals of Translational Medicine (Vol. 2, Number 6). AME Publishing Company. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2014.06.01","DOI":"10.3978\/j.issn.2305-5839.2014.06.01"},{"issue":"7","key":"49860_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070010","volume":"8","author":"T Saito","year":"2013","unstructured":"Saito, T. et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS ONE 8(7), e70010. https:\/\/doi.org\/10.1371\/journal.pone.0070010 (2013).","journal-title":"PLoS ONE"},{"issue":"1","key":"49860_CR26","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13325","volume":"24","author":"H Wu","year":"2022","unstructured":"Wu, H. et al. Metformin: A promising drug for human cancers. Oncol. Lett. 24(1), 204. https:\/\/doi.org\/10.3892\/ol.2022.13325 (2022).","journal-title":"Oncol. Lett."},{"key":"49860_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1358854","author":"L Huang","year":"2024","unstructured":"Huang, L., Woods, C. M., Dharmawardana, N., Michael, M. Z. & Ooi, E. H. The mechanisms of action of metformin on head and neck cancer in the pre-clinical setting: A scoping review. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1358854 (2024).","journal-title":"Front. Oncol."},{"issue":"6","key":"49860_CR28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41416-023-02204-2","volume":"128","author":"SR Lord","year":"2023","unstructured":"Lord, S. R. & Harris, A. L. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?. Br. J. Cancer 128(6), 958\u2013966. https:\/\/doi.org\/10.1038\/s41416-023-02204-2 (2023).","journal-title":"Br. J. Cancer"},{"issue":"8","key":"49860_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz, M., Guigas, B. & Viollet, B. Metformin: Update on mechanisms of action and repurposing potential. Nat. Rev. Endocrinol. 19(8), 460\u2013476. https:\/\/doi.org\/10.1038\/s41574-023-00833-4 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"49860_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","volume":"348","author":"MR Owen","year":"2000","unstructured":"Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348(3), 607\u2013614. https:\/\/doi.org\/10.1042\/bj3480607 (2000).","journal-title":"Biochem. J."},{"key":"49860_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.850750","author":"Y Jiao","year":"2022","unstructured":"Jiao, Y., Liu, D., Sun, Y., Chen, Z. & Liu, S. Survival benefit of metformin as an adjuvant treatment for head and neck cancer: A systematic review and meta-analysis. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.850750 (2022).","journal-title":"Front. Pharmacol."},{"issue":"5","key":"49860_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2337\/dci22-0047","volume":"46","author":"OHY Yu","year":"2023","unstructured":"Yu, O. H. Y. & Suissa, S. Metformin and cancer: Solutions to a real-world evidence failure. Diabetes Care 46(5), 904\u2013912. https:\/\/doi.org\/10.2337\/dci22-0047 (2023).","journal-title":"Diabetes Care"},{"issue":"2","key":"49860_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cncr.32539","volume":"126","author":"S Gulati","year":"2020","unstructured":"Gulati, S. et al. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. Cancer 126(2), 354\u2013362. https:\/\/doi.org\/10.1002\/cncr.32539 (2020).","journal-title":"Cancer"},{"key":"49860_CR34","doi-asserted-by":"publisher","unstructured":"Fedorov, A. A., Fedorov, E. V., Samantha, D., Hillerich, B., Seidel, R. D. & Almo, S. C. (2015). Crystal structure of human PD-L1. https:\/\/doi.org\/10.2210\/pdb4z18\/pdb","DOI":"10.2210\/pdb4z18\/pdb"},{"key":"49860_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106532","volume":"145","author":"F Wei","year":"2023","unstructured":"Wei, F. et al. Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage. Oral Oncol. 145, 106532. https:\/\/doi.org\/10.1016\/j.oraloncology.2023.106532 (2023).","journal-title":"Oral Oncol."},{"issue":"5","key":"49860_CR36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/biology12050672","volume":"12","author":"F Aguayo","year":"2023","unstructured":"Aguayo, F., Perez-Dominguez, F., Osorio, J. C., Oliva, C. & Calaf, G. M. PI3K\/AKT\/mTOR signaling pathway in HPV-driven head and neck carcinogenesis: Therapeutic implications. Biology 12(5), 672. https:\/\/doi.org\/10.3390\/biology12050672 (2023).","journal-title":"Biology"},{"issue":"13","key":"49860_CR37","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","volume":"23","author":"P Furet","year":"2013","unstructured":"Furet, P. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett. 23(13), 3741\u20133748. https:\/\/doi.org\/10.1016\/j.bmcl.2013.05.007 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"49860_CR38","doi-asserted-by":"publisher","unstructured":"Knapp, M. S. & Elling, R. A. (2014). Co-crystal Structures of the Lipid Kinase PI3K alpha with Pan and Isoform Selective Inhibitors. https:\/\/doi.org\/10.2210\/pdb4jps\/pdb","DOI":"10.2210\/pdb4jps\/pdb"},{"issue":"12","key":"49860_CR39","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1021\/jm1003842","volume":"53","author":"KD Freeman-Cook","year":"2010","unstructured":"Freeman-Cook, K. D. et al. Design of selective, ATP-competitive inhibitors of Akt. J. Med. Chem. 53(12), 4615\u20134622. https:\/\/doi.org\/10.1021\/jm1003842 (2010).","journal-title":"J. Med. Chem."},{"key":"49860_CR40","doi-asserted-by":"publisher","unstructured":"Pandit, J. (2010). Crystal structure of Akt-1-inhibitor complexes. https:\/\/doi.org\/10.2210\/pdb3mvh\/pdb","DOI":"10.2210\/pdb3mvh\/pdb"},{"key":"49860_CR41","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2021.3304","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Sun, J. & Yao, N. Correlation of the AKT\/mTOR signaling pathway with the clinicopathological features and prognosis of nasopharyngeal carcinoma. Eur. J. Histochem. https:\/\/doi.org\/10.4081\/ejh.2021.3304 (2021).","journal-title":"Eur. J. Histochem."},{"key":"49860_CR42","doi-asserted-by":"publisher","unstructured":"Pavletich, N. P. & Yang, H. (2013a). mTOR kinase structure, mechanism and regulation. https:\/\/doi.org\/10.2210\/pdb4jsv\/pdb","DOI":"10.2210\/pdb4jsv\/pdb"},{"issue":"7448","key":"49860_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","volume":"497","author":"H Yang","year":"2013","unstructured":"Yang, H. et al. mTOR kinase structure, mechanism and regulation. Nature 497(7448), 217\u2013223. https:\/\/doi.org\/10.1038\/nature12122 (2013).","journal-title":"Nature"},{"key":"49860_CR44","doi-asserted-by":"publisher","unstructured":"Pavletich, N. P. & Yang, H. (2013b). structure of mTORDeltaN-mLST8-PI-103 complex. https:\/\/doi.org\/10.2210\/pdb4jt6\/pdb","DOI":"10.2210\/pdb4jt6\/pdb"},{"issue":"11","key":"49860_CR45","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1593\/neo.08586","volume":"10","author":"A Schneider","year":"2008","unstructured":"Schneider, A., Younis, R. H. & Gutkind, J. S. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK\/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 10(11), 1295\u20131302. https:\/\/doi.org\/10.1593\/neo.08586 (2008).","journal-title":"Neoplasia"},{"issue":"1","key":"49860_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4017","volume":"4","author":"B Xiao","year":"2013","unstructured":"Xiao, B. et al. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 4(1), 3017. https:\/\/doi.org\/10.1038\/ncomms4017 (2013).","journal-title":"Nat. Commun."},{"key":"49860_CR47","doi-asserted-by":"publisher","unstructured":"Xiao, B., Sanders, M. J., Carmena, D., Bright, N. J., Haire, L. F., Underwood, E., Patel, B. R., Heath, R. B., Walker, P. A., Hallen, S., Giordanetto, F., Martin, S. R., Carling, D. & Gamblin, S. J. (2013b). Structure of full length human AMPK in complex with a small molecule activator, a benzimidazole derivative (991). https:\/\/doi.org\/10.2210\/pdb4cfe\/pdb","DOI":"10.2210\/pdb4cfe\/pdb"},{"issue":"10","key":"49860_CR48","doi-asserted-by":"publisher","first-page":"13435","DOI":"10.1007\/s13277-016-5149-0","volume":"37","author":"B Cirauqui","year":"2016","unstructured":"Cirauqui, B. et al. DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer. Tumor Biol. 37(10), 13435\u201313443. https:\/\/doi.org\/10.1007\/s13277-016-5149-0 (2016).","journal-title":"Tumor Biol."},{"issue":"1","key":"49860_CR49","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.1038\/s41467-023-41821-6","volume":"14","author":"G Cui","year":"2023","unstructured":"Cui, G. et al. An autoinhibited state of 53BP1 revealed by small molecule antagonists and protein engineering. Nat. Commun. 14(1), 6091. https:\/\/doi.org\/10.1038\/s41467-023-41821-6 (2023).","journal-title":"Nat. Commun."},{"key":"49860_CR50","doi-asserted-by":"publisher","unstructured":"Cui, G., Botuyan, M. V. & Mer, G. (2019). Structure of 53BP1 tandem Tudor domains in complex with small molecule UNC3351. https:\/\/doi.org\/10.2210\/pdb6mxy\/pdb","DOI":"10.2210\/pdb6mxy\/pdb"},{"key":"49860_CR51","doi-asserted-by":"publisher","unstructured":"Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormo, M., Nilsson, Y., Radesater, A. C., Jerning, E., Markgren, P. O., Borgegard, T., Nylof, M., Gimenez-Cassina, A., Hernandez, F., Lucas, J. J., Diaz-Mido, J. & Avila, J. (2004). crystal structure of Glycogen synthase kinase 3 in complexed with inhibitor. https:\/\/doi.org\/10.2210\/pdb1q5k\/pdb","DOI":"10.2210\/pdb1q5k\/pdb"},{"issue":"46","key":"49860_CR52","doi-asserted-by":"publisher","first-page":"45937","DOI":"10.1074\/jbc.M306268200","volume":"278","author":"R Bhat","year":"2003","unstructured":"Bhat, R. et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278(46), 45937\u201345945. https:\/\/doi.org\/10.1074\/jbc.M306268200 (2003).","journal-title":"J. Biol. Chem."},{"issue":"8","key":"49860_CR53","doi-asserted-by":"publisher","first-page":"14221","DOI":"10.18632\/oncotarget.13991","volume":"8","author":"JA McCubrey","year":"2017","unstructured":"McCubrey, J. A. et al. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget 8(8), 14221\u201314250. https:\/\/doi.org\/10.18632\/oncotarget.13991 (2017).","journal-title":"Oncotarget"},{"key":"49860_CR54","doi-asserted-by":"publisher","unstructured":"Bowman, B. R., Grossmann, T. N., Yeh, J. T.-H. & Verdine, G. L. (2012). Structure of beta-catenin in complex with a stapled peptide inhibitor. https:\/\/doi.org\/10.2210\/pdb4djs\/pdb","DOI":"10.2210\/pdb4djs\/pdb"},{"issue":"44","key":"49860_CR55","doi-asserted-by":"publisher","first-page":"17942","DOI":"10.1073\/pnas.1208396109","volume":"109","author":"TN Grossmann","year":"2012","unstructured":"Grossmann, T. N. et al. Inhibition of oncogenic Wnt signaling through direct targeting of \u03b2-catenin. Proc. Natl. Acad. Sci. U. S. A. 109(44), 17942\u201317947. https:\/\/doi.org\/10.1073\/pnas.1208396109 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"49860_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna9050063","volume":"9","author":"A Sajeev","year":"2023","unstructured":"Sajeev, A. et al. Crosstalk between non-coding RNAs and Wnt\/\u03b2-Catenin signaling in head and neck cancer: Identification of novel biomarkers and therapeutic agents. Noncoding RNA 9(5), 63. https:\/\/doi.org\/10.3390\/ncrna9050063 (2023).","journal-title":"Noncoding RNA"},{"key":"49860_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.799993","author":"T de Bakker","year":"2022","unstructured":"de Bakker, T. et al. Restoring p53 function in head and neck squamous cell carcinoma to improve treatments. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.799993 (2022).","journal-title":"Front. Oncol."},{"key":"49860_CR58","doi-asserted-by":"publisher","unstructured":"Wang, Y., Rosengarth, A. & Luecke, H. (2007a). Human p53 core domain in the absence of DNA. https:\/\/doi.org\/10.2210\/pdb2ocj\/pdb","DOI":"10.2210\/pdb2ocj\/pdb"},{"issue":"3","key":"49860_CR59","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1107\/S0907444906048499","volume":"63","author":"Y Wang","year":"2007","unstructured":"Wang, Y., Rosengarth, A. & Luecke, H. Structure of the human p53 core domain in the absence of DNA. Acta Crystallogr. D Biol. Crystallogr. 63(3), 276\u2013281. https:\/\/doi.org\/10.1107\/S0907444906048499 (2007).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"49860_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00176","author":"W-C Li","year":"2020","unstructured":"Li, W.-C. et al. Regulatory role of hexokinase 2 in modulating head and neck tumorigenesis. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.00176 (2020).","journal-title":"Front. Oncol."},{"key":"49860_CR61","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171666","author":"MH Nawaz","year":"2018","unstructured":"Nawaz, M. H. et al. The catalytic inactivation of the N-half of human hexokinase 2 and structural and biochemical characterization of its mitochondrial conformation. Biosci. Rep. https:\/\/doi.org\/10.1042\/BSR20171666 (2018)."},{"key":"49860_CR62","doi-asserted-by":"publisher","unstructured":"Rabeh, W. M., Zhu, H., Nedyalkova, L., Tempel, W., Wasney, G., Landry, R., Vedadi, M., Arrowsmith, C. H., Edwards, A. M., Sundstrom, M., Weigelt, J., Bochkarev, A., Park, H., & Structural Genomics Consortium (SGC). (2006). Crystal structure of human hexokinase II. https:\/\/doi.org\/10.2210\/pdb2nzt\/pdb","DOI":"10.2210\/pdb2nzt\/pdb"},{"key":"49860_CR63","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume-title":"Methods in Molecular Biology","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. In Methods in Molecular Biology Vol. 1263 243\u2013250 (Humana Press, 2015). https:\/\/doi.org\/10.1007\/978-1-4939-2269-7_19."},{"issue":"1","key":"49860_CR64","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7(1), 42717. https:\/\/doi.org\/10.1038\/srep42717 (2017).","journal-title":"Sci. Rep."},{"issue":"1\u20133","key":"49860_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23(1\u20133), 3\u201325. https:\/\/doi.org\/10.1016\/S0169-409X(96)00423-1 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"W1","key":"49860_CR66","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","volume":"52","author":"P Banerjee","year":"2024","unstructured":"Banerjee, P., Kemmler, E., Dunkel, M. & Preissner, R. ProTox 3.0: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 52(W1), W513\u2013W520. https:\/\/doi.org\/10.1093\/nar\/gkae303 (2024).","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"49860_CR67","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","volume":"29","author":"S Pronk","year":"2013","unstructured":"Pronk, S. et al. GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29(7), 845\u2013854. https:\/\/doi.org\/10.1093\/bioinformatics\/btt055 (2013).","journal-title":"Bioinformatics"},{"issue":"2","key":"49860_CR68","doi-asserted-by":"publisher","DOI":"10.1063\/1.2136877","volume":"124","author":"Y Wu","year":"2006","unstructured":"Wu, Y., Tepper, H. L. & Voth, G. A. Flexible simple point-charge water model with improved liquid-state properties. J. Chem. Phys. 124(2), 024503. https:\/\/doi.org\/10.1063\/1.2136877 (2006).","journal-title":"J. Chem. Phys."},{"issue":"8","key":"49860_CR69","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/prot.22711","volume":"78","author":"K Lindorff\u2010Larsen","year":"2010","unstructured":"Lindorff\u2010Larsen, K. et al. Improved side\u2010chain torsion potentials for the Amber ff99SB protein force field. Proteins 78(8), 1950\u20131958. https:\/\/doi.org\/10.1002\/prot.22711 (2010).","journal-title":"Proteins"},{"issue":"16","key":"49860_CR70","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","volume":"26","author":"DA Case","year":"2005","unstructured":"Case, D. A. et al. The Amber biomolecular simulation programs. J. Comput. Chem. 26(16), 1668\u20131688. https:\/\/doi.org\/10.1002\/jcc.20290 (2005).","journal-title":"J. Comput. Chem."},{"issue":"9","key":"49860_CR71","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1021\/ct400314y","volume":"9","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer, R., G\u00f6tz, A. W., Poole, D., Le Grand, S. & Walker, R. C. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. J. Chem. Theory Comput. 9(9), 3878\u20133888. https:\/\/doi.org\/10.1021\/ct400314y (2013).","journal-title":"J. Chem. Theory Comput."},{"issue":"9","key":"49860_CR72","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller","year":"2012","unstructured":"Miller, B. R. et al. MMPBSA.py: An efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8(9), 3314\u20133321. https:\/\/doi.org\/10.1021\/ct300418h (2012).","journal-title":"J. Chem. Theory Comput."},{"issue":"3","key":"49860_CR73","doi-asserted-by":"publisher","first-page":"443","DOI":"10.32708\/uutfd.1728900","volume":"51","author":"\u00c7Z K\u00f6pr\u00fc","year":"2025","unstructured":"K\u00f6pr\u00fc, \u00c7. Z., Baba, B., Ahmed Naji, S., Y\u0131ld\u0131z, \u0130 & Akbay, A. Some benzoxazole derivatives as potential mTOR inhibitors: Anticancer activity and molecular docking studies in breast cancer. Uludag Univ. Tip Fak. Derg. 51(3), 443\u2013450. https:\/\/doi.org\/10.32708\/uutfd.1728900 (2025).","journal-title":"Uludag Univ. Tip Fak. Derg."},{"issue":"1","key":"49860_CR74","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1080\/10717544.2021.1977422","volume":"28","author":"Y Xie","year":"2021","unstructured":"Xie, Y. et al. Network pharmacology and experimental investigation of Rhizoma polygonati extract targeted kinase with herbzyme activity for potent drug delivery. Drug Deliv. 28(1), 2187\u20132197. https:\/\/doi.org\/10.1080\/10717544.2021.1977422 (2021).","journal-title":"Drug Deliv."},{"issue":"9","key":"49860_CR75","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1334983\/v1","volume":"36","author":"SS Hassan","year":"2022","unstructured":"Hassan, S. S. et al. The dual therapeutic effect of Metformin nuclei based drugs modified with one of Tulbaghia violacea extract compounds. Appl. Organomet. Chem. 36(9), e6804. https:\/\/doi.org\/10.21203\/rs.3.rs-1334983\/v1 (2022).","journal-title":"Appl. Organomet. Chem."},{"issue":"4","key":"49860_CR76","doi-asserted-by":"publisher","first-page":"821","DOI":"10.31557\/apjcb.2025.10.4.821-835","volume":"10","author":"SR Salih","year":"2025","unstructured":"Salih, S. R., Majeed, A. H., Hussein, K. M., Yasin, Y. S. & Jumaa, A. H. Dual drug repurposing in cervical cancer: The synergistic cytotoxic effect of Dapagliflozin-Etoricoxib and its predicted modulation of PI3K\/Akt\/mTOR signaling via molecular docking. Asian Pacific J. Cancer Biol. 10(4), 821\u2013835. https:\/\/doi.org\/10.31557\/apjcb.2025.10.4.821-835 (2025).","journal-title":"Asian Pacific J. Cancer Biol."},{"issue":"10","key":"49860_CR77","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.3390\/biomedicines11102688","volume":"11","author":"NS Al-Zahrani","year":"2023","unstructured":"Al-Zahrani, N. S., Zamzami, M. A., Baghdadi, M. A., El-Gowily, A. H. & Ali, E. M. M. Regulation of protein-induced apoptosis and autophagy in human hepatocytes treated with metformin and paclitaxel in silico and in vitro. Biomedicines 11(10), 2688. https:\/\/doi.org\/10.3390\/biomedicines11102688 (2023).","journal-title":"Biomedicines"},{"issue":"28","key":"49860_CR78","doi-asserted-by":"publisher","first-page":"24858","DOI":"10.1021\/acsomega.2c03079","volume":"7","author":"I Shawish","year":"2022","unstructured":"Shawish, I. et al. Synthesis and antiproliferative activity of a new series of mono- and bis(dimethylpyrazolyl)-s-triazine derivatives targeting EGFR\/PI3K\/AKT\/mTOR signaling cascades. ACS Omega 7(28), 24858\u201324870. https:\/\/doi.org\/10.1021\/acsomega.2c03079 (2022).","journal-title":"ACS Omega"},{"key":"49860_CR79","doi-asserted-by":"publisher","DOI":"10.2174\/0115734064346419241104110015","author":"VMR Mythili","year":"2025","unstructured":"Mythili, V. M. R. et al. Marine-derived compound targeting mTOR and FGFR-2: A promising strategy for breast, lung, and colorectal cancer therapy. Med. Chem. https:\/\/doi.org\/10.2174\/0115734064346419241104110015 (2025).","journal-title":"Med. Chem."},{"issue":"3","key":"49860_CR80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5155\/eurjchem.11.3.223-234.2004","volume":"11","author":"P Kumar","year":"2020","unstructured":"Kumar, P. et al. Antiproliferative potential, quantitative structure-activity relationship, cheminformatic and molecular docking analysis of quinoline and benzofuran derivatives. Eur. J. Chem. 11(3), 223\u2013234. https:\/\/doi.org\/10.5155\/eurjchem.11.3.223-234.2004 (2020).","journal-title":"Eur. J. Chem."}],"updated-by":[{"DOI":"10.1038\/s41598-026-60311-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49860-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49860-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49860-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:38:41Z","timestamp":1782916721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49860-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49860"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49860-x","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20171666","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-60311-5","URL":"https:\/\/doi.org\/10.1038\/s41598-026-60311-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19371"}}